GSTM1 and metabolic disease: Aggregated analysis of phase II/III clinical trials demonstrated that roxadustat could increase serum Hb levels compared with ESAs in patients with CKD undergoing HD, without being affected by blood iron metabolism disorders and inflammation, which was confirmed by the post-marketing study.